Zydus Lifesciences Ltd on Saturday said the US health regulator has completed an on-site inspection of the pharmacovigilance and post-marketing surveillance system at its office in New Jersey, USA, with nil observations.
The inspection by the US Food and Drug Administration (USFDA) was conducted from September 22 to September 25, 2026, the company said in a regulatory filing.
“The inspection closed with NIL observations,” Zydus Lifesciences stated.
Published on September 26, 2026
